17 Aug Tyrosine kinase inhibitors
Posted at 12:41h
in
The pharmaceutical companies mentioned below, in collaboration with South African Health Products Regulatory Authority (SAHPRA), wish to inform you of the class related cerebrovascular adverse events reported with the use of tyrosine kinase inhibitor (TKI) containing medicines. The Professional Information (PI) and Patient Information Leaflet (PIL) of these products will be amended to reflect this safety issue.
2020 Jun
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
18/06/2020
File Type:
pdf
Category:
Communication To Health Care Professionals